BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 8, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors. Mr.

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 8, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced operating results for the three months ended June 30, 2022 .

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Canaccord Genuity 42 nd Annual

BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 1, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced it will host a conference call on Monday, August 8, 2022 , to discuss its second quarter 2022 financial

Company to present results of validation study at 2022 Alzheimer’s Association International Conference BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 27, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 9, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue , will join the Goldman Sachs 43 rd Annual

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 6, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn , Senior Vice President and Chief Commercial Officer of Catalent Pharma

Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research BILLERICA, Mass. --(BUSINESS WIRE)--May 10, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision

BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2022 before the start of trading

Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 22, 2022-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing